Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease

Comparative Effectiveness and Safety of Anti–Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn’s Disease

(2016) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial

(2016) Takayuki Matsumoto et al.   Journal of Crohns & Colitis

Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience

(2016) Laurent Peyrin-Biroulet et al.   Journal of Crohns & Colitis

Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

(2015) Sarah S. Thomas et al.   BIODRUGS

Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease

(2015) Walter Reinisch et al.   Clinical Gastroenterology and Hepatology

Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation

(2015) Nikos Viazis et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

(2015) Reena Khanna et al.   LANCET

Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis

(2014) Uri Kopylov et al.   Journal of Crohns & Colitis

Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease

(2013) Mark T. Osterman et al.   Clinical Gastroenterology and Hepatology

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

(2013) Mark T. Osterman et al.   GASTROENTEROLOGY

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease

(2013) Ole Haagen Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

(2012) C. Reenaers et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study

(2012) Parakkal Deepak et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Factors affecting outcomes in Crohn's disease over 15 years

(2012) Jacques Cosnes et al.   GUT

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

(2010) H. Sokol et al.   GUT

Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease

(2009) Josh Marehbian et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY